Overview
Trasis designs, manufactures, sells and supports synthesizers, dose preparation and dispensing equipment, consumables and shielding used to prepare radiopharmaceuticals. The company was founded in 2004 by Jean-Luc Morelle and Gauthier Philippart, who had worked together at Coincidence Technologies, a radio-synthesizer company Morelle set up in 1996 and General Electric acquired in 2001. Its product range includes the Unidose and Quickfill dispensers introduced in 2008, the AllinOne synthesizer in 2010, the miniAllinOne in 2012 and the EasyOne in 2019. Revenue grew from 25 million EUR in 2020 to 70 million EUR in 2023, 72 million EUR in 2024 and 85 million EUR in 2025, with exports above 98% of sales and technology in use in around 60 countries. Headcount was around 470 in May 2026, 420 of them in Ans, and the company has said it aims for about 700 people by 2030. A 5,000 m2 extension in Ans opened in April 2024. Eras Labo near Grenoble and Trasis Inc. in Atlanta joined the group, a majority-held joint venture named Trasis Beijing was announced in November 2025, and in May 2026 Trasis bought the former Mithra CDMO plant in Flemalle. EY named the company Entreprise de l'Annee 2025.
Funding history
- 2022 Eras Labo: Eras Labo of Saint-Nazaire-les-Eymes near Grenoble, a contract chemistry company with 25 employees and 1,000 m2 of laboratories, joined forces with Trasis in an announcement dated 14 October 2022; the company timeline lists it as joining the group in 2023
- 2023 Trasis Inc.: US subsidiary Trasis Inc. created in Atlanta
- 2025 Trasis Beijing: Majority-held joint venture with Beijing PET Technology announced 25 November 2025, closing early 2026
- 2026 Flemalle site: Acquisition of the former Mithra CDMO plant in Flemalle, 6 hectares and 17,000 m2, part of a 40 million EUR investment plan with 300 jobs targeted by 2030
Stated facts & numbers
- Founded: 2004
- Headquarters: Rue Gilles Magnee 90, Ans (Liege)
- Founders: Gauthier Philippart and Jean-Luc Morelle
- CEO: Gauthier Philippart (co-founder)
- CTO: Jean-Luc Morelle (co-founder)
- Employees: About 470 worldwide (May 2026), 420 in Ans
- Revenue 2025: 85 million EUR
- Revenue 2024: 72 million EUR
- Exports: More than 98% of sales
- Markets: Around 60 countries
- Products: AllinOne, miniAllinOne, EasyOne, Unidose, Quickfill
- Sites: Ans and Flemalle (Belgium), Saint-Nazaire-les-Eymes (France), Tucker GA (USA), Beijing (China)
- R&D spend: More than 5 million EUR a year
- Awards: EY Entreprise de l'Annee 2025; AWEX Golden Export Award 2022; EY Scale Up Award 2018
In the news
- A promising radiotracer is only the beginning. What does it take to reach patients? The path from development to commercialisation is complex, involving R&D, clinical validation, GMP manufacturing, regulatory compliance, and industrial deployment. Each step must be aligned to avoid delays and reduce risk. At Trasis, we provide a turnkey, end-to-end solution tailored to the needs of diagnostic and theranostic radiotracer projects. By connecting expertise across the entire value chain, we help accelerate time-to-market while
- Plenty of opportunities to connect by the end of the year. Our teams will be attending seven events across the United States, Europe and North Africa in November and December. Here's where you can meet us: 📍 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 🔹SNMMI Theranostics Conference | November 4-7 | Bethesda, USA | Emmanuel (Manu) Bertrand, David Starr & Elena Parkhomenko 🔹Radiopharma Facility Design, Engineering and Construction Summit | November 18-19 | Indianapolis, USA | Emmanuel (Manu) Bertrand & David Starr 🔹NVNG Autumn Congress 2026 | November 20
- Thank you BioWin for two inspiring days with the Belgian nuclear medicine community. Our CEO Gauthier Philippart ’s ambition for 2035: a radiopharmaceutical created and developed in Belgium that improves patient care worldwide, and whose success is reinvested here in the next molecules. From molecule to patient. Together. #NuclearMedicineInBelgium #NuclearMedicine #BioWin
- Nuclear Medicine in Belgium 2026 – The energy, the ideas, the connections. Relive it all! One day. Inspiring discussions. Meaningful connections. One shared ambition. One week ago in Namur, BioWin brought together Belgian and international experts from industry, research, healthcare and regulatory authorities to connect expertise, foster collaboration and shape the future of nuclear medicine. 🚀 💡 From insightful discussions to new opportunities for collaboration, this event highlighted the strength of Belgium's ecosystem and
- Detect. Treat. Rebuild.🌸 So many steps that cancer patients have to go through. At Trasis, our mission is to provide solutions that contribute to a future where cancer and degenerative diseases are no longer synonymous with suffering and loss of life. In nuclear medicine, our technologies make it possible to produce the radiotracers used in imaging to detect cancer and pave the way for increasingly targeted treatments. By supporting innovation, we aim to bring it as quickly as possible to the patients who are waiting for it.
- Four days in Vienna, and what days they were! EANM’26 was a truly special edition for Trasis, and we owe it to all of you. Beyond the booth, our side events brought the community together: 🔹 Partner Meeting: 20+ distributors from around the world, aligned on the year ahead 🔹 Community Meeting: 100+ radiochemists, radiopharmacists, physicians and industry experts, with inspiring talks from Memorial Sloan Kettering Cancer Center, St. Olavs hospital, Trondheim University Hospital, Médecine Nucléaire Tourangelle and Trasis 🔹
- One room, four perspectives: an academic cancer center, a hospital PET production site, a nuclear medicine center and industry. At our Community Meeting at EANM26 in Vienna, radiochemists, radiopharmacists and physicians compared notes on a shared challenge: getting promising tracers to patients, reliably. 🔹 Serge K. Lyashchenko (Memorial Sloan Kettering Cancer Center) showed how isotope access, regulation, training and cost shape clinical translation as much as the science. 🔹 Jin Han (St. Olavs hospital, Trondheim University
- Thank you BioWin for bringing together the people and organisations contributing to this ambition.
Something wrong or missing? Send an update. Fixed within 24 hours.